Alnylam Pharmaceuticals (ALNY) Beats Q4 Earnings and Revenue EstimatesZacks Investment Research • 02/13/25
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period ProgressBusiness Wire • 02/13/25
Ahead of Alnylam (ALNY) Q4 Earnings: Get Ready With Wall Street Estimates for Key MetricsZacks Investment Research • 02/10/25
Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 02/06/25
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial ResultsBusiness Wire • 01/30/25
Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year?Zacks Investment Research • 01/21/25
ALNY Announces Preliminary 2024 Results, 2025 View & Pipeline GoalsZacks Investment Research • 01/13/25
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline GoalsBusiness Wire • 01/12/25
Alnylam Pharmaceuticals: Commercialization And Early-Stage Studies Are Likely To Drive 2025Seeking Alpha • 01/07/25
Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/06/25
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare ConferenceBusiness Wire • 11/27/24
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with CardiomyopathyBusiness Wire • 11/25/24
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis StudyZacks Investment Research • 11/18/24